HTG Molecular Diagnostics Announces Distribution Agreements with Gamidor in Israel and Durviz in Spain and Portugal

HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced distribution agreements with Gamidor Diagnostics (“Gamidor”) in Israel and Durviz s.l. Parque Tecnológico de Valencia (“Durviz”) in Spain and Portugal to manage distribution of HTG’s next generation sequencing (NGS)-based products.
According to the news:

Gamidor provides systems, chemicals, reagents and services in Israel, offering state-of-the-art diagnostic solutions to hospitals, health management systems and academic research institutes.  Durviz is a distributor of next-generation sequencing reagents and library preparation systems in Spain and Portugal.

Jean Claude Gerard, PhD, VP European Commercial Operations for HTG Molecular Diagnostics commented:

By expanding our distribution reach into these markets, we believe the availability of the HTG EdgeSeq system and assays will accelerate the adoption of molecular profiling using NGS. Both Gamidor and Durviz are as passionate as we are at HTG about enabling precision medicine at the local level.

Click here to view the full press release.